Clinical Study Investigates 'Obesity Paradox' in Treatment of Non-Small Cell Lung Cancer
August 5th 2024Multiple observational studies have shown that patients with cancer and a higher body mass index who were administered chemotherapy experienced improved survival compared to patients with normal body weight.
Oral Semaglutide Shows Improved Energy Intake, Appetite, Eating Control in Adults with Obesity
July 31st 2024Randomized trial finds once daily oral semaglutide 50 mg lowered energy intake, appetite, and food cravings, with improved control of eating and clinically meaningful reductions in body weight after 20 weeks.
Trial Results Suggest Older GLP-1 Drug May Slow Cognitive Decline in Alzheimer Patients
July 30th 2024Phase IIb trial indicates liraglutide (Novo Nordisk) may reduce cognitive decline associated with Alzheimer disease by protecting against shrinkage in areas of the brain controlling memory, learning, language, and decision-making.
DIA's Impact on the Clinical Research Industry
July 26th 2024In the fifth and final part of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA touches on how the organization continues to break down silos in clinical research and provide a medium for collaboration.
DIA's Objectives for the Remainder of 2024
July 25th 2024In part 4 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA discusses how the organization is looking to expand into different global regions and continue leading awareness for the clinical research industry.